Abstract 4897
Background
A noninvasive cfDNA test to detect early-stage pancreatic ductal adenocarcinoma (PDAC) is highly desirable to reduce PDAC’s high mortality rate. DNA methylation markers are promising to differentiate PDAC tissues from benign pancreas tissues, which may lead to liquid biopsy tests for PDAC early screening.
Methods
We have collected freshly frozen clinical PDAC tissues (N = 46), para-tumour pancreas tissues (N = 30), PDAC plasma samples (N = 120), chronical pancreatitis plasma samples (N = 90), and normal plasma samples (N = 100). Genomic DNA and circulating tumour DNA (ctDNA) samples were isolated and purified. DNA methylation profiles were generated by reduced representation bisulfite sequencing (RRBS). We quantified DNA methylation status of Methylation Haplotype Blocks (MHB) using Methylation Haplotype Load (MHL). Tumour-specific DNA methylation signatures were identified for PDAC by comparing MHL scores between PDAC and para-tumour pancreas tissues, PDAC tissues with normal cell-free circulating DNA (cfDNA), and PDAC ctDNA with normal cfDNA samples.
Results
We identified 350 of MHBs by combining unique MHBs identified in each comparison. Using MHB selected from tissue-vs-tissue comparison to build classifiers, we reiterated training and cross-validating PDAC tissue classification models using SVM method, and achieved the average sensitivity of 86% specificity of 88%, and AUC of 0.91. Other machine learning methods generated similar results. We further compared our markers with previously published DNA methylation markers for PDAC, and found that genes associated with published markers are highly enriched in the genes associated with our markers (p < 1E-20; hypergeometric test), indicating they may co-regulate a same set of genes that are involved in PDAC pathology. We have further developed NGS based panels and algorithms to classify PDAC patients using cell-free DNA (cfDNA) samples based on the identified methylation markers.
Conclusions
Using multiple metrics on MHBs, we identified PDAC-specific DNA methylation markers, some of which are functionally overlapped with previously reported markers. These markers are candidate biomarkers for non-invasive PDAC screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Peking Union Medical College Hospital and Singlera Genomics Inc.
Funding
China Science and Technology Exchange Center.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1025 - Liver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): Outcomes from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging.
Presenter: Angela Lamarca
Session: Poster Display session 2
Resources:
Abstract
5813 - Is MGMT methylation a new therapeutic target for Biliary Tract Cancer?
Presenter: Monica Niger
Session: Poster Display session 2
Resources:
Abstract
5839 - Biliary Tract Cancers in Portuguese families with BRCA gene mutation: a retrospective study.
Presenter: Patricia Pereira
Session: Poster Display session 2
Resources:
Abstract
4338 - Selection of patients with hepatocellular carcinoma for selective internal radiation therapy based on tumour burden and liver function: a post-hoc analysis of the SARAH trial
Presenter: Daniel Palmer
Session: Poster Display session 2
Resources:
Abstract
1700 - Second-line chemotherapy (SLC) in Patients with Advanced Biliary tract and Gallbladder Cancers (ABGC) Prolongs Survival: A Retrospective Population-based Cohort Study
Presenter: Adnan Zaidi
Session: Poster Display session 2
Resources:
Abstract
5562 - Overall survival of patients with hepatocellular carcinoma receiving sorafenib versus selective internal radiation therapy with predicted dosimetry in the SARAH trial
Presenter: Neil Hawkins
Session: Poster Display session 2
Resources:
Abstract
1838 - Multicenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy
Presenter: Naohiro Okano
Session: Poster Display session 2
Resources:
Abstract
3641 - Soluble Programmed Death-ligand 1 indicate poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization
Presenter: Xiaolu Ma
Session: Poster Display session 2
Resources:
Abstract
2733 - The Prognostic Nutritional Index (PNI) is an independent predictor of survival in advanced biliary cancers (ABC) receiving first-line chemotherapy (1L).
Presenter: Francesco Caputo
Session: Poster Display session 2
Resources:
Abstract
3773 - Impact of centralisation of national cancer services on patient outcomes for hepatobiliary cancers in Ireland 2000 – 2016
Presenter: David O Reilly
Session: Poster Display session 2
Resources:
Abstract